Pharmacogenomic Testing: What to Know Before Ordering

What is pharmacogenomic testing?

Pharmacogenomic testing, often shortened to PGx testing, is genetic testing that looks for DNA variants associated with medication response. MedlinePlus describes pharmacogenetic tests as tests that use a blood, saliva, or cheek-swab sample to look for gene changes that may affect whether a medicine works well, what dose may be needed, or whether a person may be more likely to have certain serious side effects. See the National Library of Medicine’s overview of pharmacogenetic tests for a patient-friendly explanation.

The word sounds broad, and it is. Some PGx tests focus on a single gene and one medication decision. Others are multi-gene panels that report on dozens or hundreds of medications. A test may examine genes involved in drug metabolism, drug transport, immune reactions, or drug targets. For example, CYP2D6 and CYP2C19 affect metabolism of many psychiatric, pain, cardiovascular, and gastrointestinal medicines; HLA genes can identify people at higher risk for certain severe immune-mediated reactions; and DPYD variants can affect risk of severe toxicity from some fluoropyrimidine chemotherapy drugs.

The U.S. Food and Drug Administration maintains a Table of Pharmacogenomic Biomarkers in Drug Labeling and a separate Table of Pharmacogenetic Associations. These resources show that drug labels and evidence vary: some gene-drug pairs include clear prescribing actions, while others provide information about metabolism or risk without requiring a specific change.

What pharmacogenomic testing can and cannot tell you

A useful way to think about pharmacogenomic testing is that it adds one layer of information to medication decision-making. It can help answer questions such as: Do you metabolize a medication unusually quickly or slowly? Are you more likely to have a severe reaction to a specific drug? Is a standard dose likely to produce unusually high or low exposure? Should your clinician consider an alternative medication or closer monitoring?

It cannot answer every medication question. A PGx result does not prove that a drug will work, rule out all side effects, diagnose a condition, or replace clinical judgment. Medication response is influenced by many non-genetic factors, including age, kidney and liver function, pregnancy, smoking status, diet, alcohol use, drug interactions, adherence, diagnosis, disease severity, and the dose actually taken. The Centers for Disease Control and Prevention notes that pharmacogenomics can help clinicians understand whether some medicines are likely to benefit a person or be safe, but it is currently used for only some drugs; see the CDC’s pharmacogenomics overview.

It is also important to separate analytic validity from clinical usefulness. A lab may accurately detect a genetic variant, but the result is most valuable when there is strong evidence that the variant should change prescribing. The Clinical Pharmacogenetics Implementation Consortium, or CPIC, publishes peer-reviewed guidelines that help clinicians translate genotype results into prescribing recommendations when a result is already available. CPIC’s guideline library is one of the most widely used clinical references for drug-gene interpretation.

Who may benefit from PGx testing?

Pharmacogenomic testing is most likely to help when there is a medication decision that matches a well-supported drug-gene relationship. Examples include a person who has had unexpected side effects at normal doses, someone who has not responded as expected to multiple medications, a patient being considered for a drug with a known genetic safety issue, or someone starting a medicine for which genotype-guided dosing is included in guidelines or labeling.

PGx testing may also be useful when a person takes multiple medicines and is at risk for drug-drug interactions layered on top of drug-gene interactions. For example, a person may genetically metabolize a drug normally, but another medication may inhibit the same enzyme and make them function more like a slow metabolizer. A good report and a good interpreter should consider the current medication list, not just the DNA result.

Testing is less likely to be helpful when it is ordered as a broad curiosity test with no relevant medication question, when the panel does not include the medication being considered, or when the medication’s response is not strongly tied to the genes tested. A report may look impressive while still providing little actionable information for your situation.

Common drug-gene examples you may see on a report

Different laboratories use different panels and interpretation systems, so your report may not include all of these examples. The table below is meant to explain the kinds of drug-gene relationships PGx testing may address, not to recommend any specific treatment.

FDA labeling tables and CPIC guidelines do not always match perfectly because they serve different purposes. FDA resources describe labeling and associations that the agency has evaluated, while CPIC provides genotype-to-prescribing recommendations for clinicians when results are available. If a commercial report gives a color-coded recommendation, ask whether the recommendation is based on FDA labeling, CPIC, another professional guideline, the lab’s proprietary algorithm, or a combination.

How to read a pharmacogenomic report

PGx reports often include several terms that can be confusing at first.

Genotype

Your genotype is the specific variant pattern detected by the test. For pharmacogenes, labs may use “star allele” names such as CYP2D6 *1/*4 or CYP2C19 *1/*17. A genotype is a laboratory finding; it is not, by itself, the prescribing answer.

Phenotype

The phenotype is the predicted functional category inferred from the genotype. Common metabolism phenotypes include poor metabolizer, intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer. The meaning depends on the drug. For one medication, poor metabolism may increase side-effect risk because the parent drug builds up. For another, poor metabolism may reduce benefit because the medication must be converted into an active metabolite.

Medication category or color

Many reports group medicines into categories such as “use as directed,” “use with caution,” or “consider alternatives.” These categories are not universal. A green category does not guarantee success, and a red category does not always mean a medication is forbidden. It means the prescribing clinician should interpret the result in context.

Actionability

The most important question is whether the result should change care now. A result may be interesting but not actionable if you are not taking that medication, if an alternative is not appropriate, or if the evidence is weak. Conversely, a single-gene result can be highly actionable if you are about to start a medication with a well-established genetic safety issue.

How the test is collected and how to prepare

Most pharmacogenomic tests use a cheek swab, saliva sample, or blood draw. Cheek-swab and saliva kits may be collected in a clinic or at home, depending on the ordering route. Blood draws are usually collected at a lab, clinic, hospital, or patient service center.

Preparation is usually simple, but follow the exact kit instructions. For cheek-swab or saliva testing, many labs ask you not to eat, drink, smoke, vape, chew gum, or brush your teeth for a short period before collection; Mayo Clinic Press gives a common example of avoiding anything in the mouth for at least 30 minutes before a cheek swab in its article on what pharmacogenomic testing is and who it is for. Blood testing usually does not require those mouth-related restrictions.

Before the sample is collected, have an up-to-date medication and supplement list ready. Include prescription drugs, over-the-counter medicines, vitamins, herbal products, recreational substances, nicotine, and recent medication changes. The gene result is only one part of interpretation; drug-drug interactions and clinical factors can be just as important.

Also tell the ordering clinician if you have had a liver transplant, stem-cell transplant, bone-marrow transplant, or recent blood transfusion. These situations can complicate some genetic-test interpretation depending on the sample type and clinical context.

Key limitations to understand before you order

Not all genes and variants are tested

Many PGx tests look only for selected variants. If your result says “normal metabolizer,” it usually means no tested variants were found that changed the lab’s predicted phenotype. It does not mean every possible variant was examined. This matters more for genes with complex structure, such as CYP2D6, where copy number changes and hybrid alleles can be technically challenging.

Not all medications have strong PGx evidence

Some drug-gene pairs have strong clinical recommendations; others have limited, preliminary, or inconsistent evidence. The FDA has warned about pharmacogenetic tests marketed with claims that predict response to specific medications when the relationship has not been established, because changing treatment based on unsupported claims could cause harm. The FDA’s consumer information on direct-to-consumer tests discusses concerns about unsupported pharmacogenetic claims.

Mental health testing is useful, but not magic

Psychiatry is one of the most common reasons consumers hear about pharmacogenomic testing. The evidence is nuanced. PGx panels may help clinicians avoid medications with predicted drug-gene interactions, especially for medications affected by CYP2D6 or CYP2C19. However, a test cannot diagnose depression, identify the “best” antidepressant with certainty, or predict response from genetics alone. The VA PRIME Care trial found that pharmacogenomic testing reduced prescribing of antidepressants with predicted drug-gene interactions; symptom-remission effects were more modest and should be interpreted in context. The VA summarizes the trial in its publication brief on pharmacogenomic testing and depression prescribing.

Reports can become outdated

Your inherited genotype generally remains stable, but the interpretation can change. New evidence, updated CPIC guidelines, FDA label changes, new medications, and improved allele definitions may alter how a result should be used. Keep a copy of your raw genotype and the full report, not just a screenshot of the color-coded medication list.

Cost, insurance, and ordering routes

Pharmacogenomic testing costs vary because the market includes single-gene tests, focused panels, psychiatric panels, broad multi-specialty panels, hospital-based testing, reference-lab testing, and direct-to-consumer reports. The total cost can include more than the lab assay: clinician visit, telehealth review, specimen collection, interpretation, genetic counseling, pharmacist consultation, shipping, and follow-up may be separate.

Insurance coverage is inconsistent. Some plans cover PGx testing when there is a documented medical need and a specific drug-gene decision. Others consider broad panels investigational or limit coverage to certain genes, medications, diagnoses, or prior-authorization criteria. Medicare coverage also depends on the applicable contractor policy, medical necessity, documentation, and the exact test billed. One example is the CMS Medicare Coverage Database entry for MolDX pharmacogenomics testing, which describes coverage indications and limitations for certain jurisdictions.

Do not compare options by the advertised lab price alone. The effective cost to the patient is the amount you may actually owe after adding mandatory fees and subtracting any covered benefits or assistance. Ask for the all-in estimate in writing when possible, including the lab charge, provider order fee, telehealth fee, collection fee, shipping, interpretation, and follow-up visit.

Privacy and genetic-discrimination considerations

PGx results are genetic information. If the test is ordered through a healthcare provider and billed through insurance, the result may become part of your medical record. That can be useful because future prescribers can see the result, but it also means you should understand who can access it and how it may be shared.

In the United States, the Genetic Information Nondiscrimination Act, or GINA, generally protects against genetic discrimination in health insurance and employment. However, GINA does not provide the same protections for life insurance, disability insurance, or long-term care insurance. The National Human Genome Research Institute explains these protections and limits in its resources on genetic discrimination.

Before ordering, read the consent and privacy policy. Look for whether your sample is destroyed or stored, whether de-identified data may be used for research or product development, whether you can opt out of data sharing, and how to request deletion when allowed. If a test is direct-to-consumer, also check whether the company is a HIPAA-covered entity or follows a different consumer privacy framework.

Questions to ask before ordering pharmacogenomic testing

• What medication decision are we trying to improve? If there is no decision, testing may be less useful.
• Which genes and variants are included? Ask for a gene list, not just the number of medications on the report.
• Which guidelines support the recommendation? Ask whether the report uses FDA labeling, CPIC, PharmGKB annotations, professional society guidelines, or proprietary algorithms.
• Is the lab CLIA-certified? Clinical testing should be performed in a laboratory certified for clinical use.
• Will insurance be billed? If yes, ask what happens if the claim is denied.
• What is my total expected out-of-pocket cost? Include ordering, collection, shipping, interpretation, and follow-up.
• Who will explain the results? Ideally, this is a prescribing clinician, pharmacist, genetic counselor, or clinician trained in pharmacogenomics.
• Will the result be added to my medical record? If yes, ask how future prescribers will be alerted to actionable results.
• Can I receive the genotype details? Keeping the full report can help if interpretation changes later.

What to do after you receive results

Start by reviewing the report with the clinician who manages the medication in question. Bring your current medication list and any past medication problems, including side effects, lack of response, dose changes, allergies, and hospitalizations. A PGx result is most useful when paired with your real treatment history.

If the report flags a current medication, do not assume it must be stopped. The safest next step may be no change, dose adjustment, closer monitoring, a blood level, a different medication, or a gradual taper. The right plan depends on why you take the medicine, how well it works, what alternatives exist, and the risk of changing therapy.

Store the report where future prescribers can access it. If your health system can add discrete PGx results to the electronic record, future prescriptions may trigger clinical decision-support alerts. If not, keep a copy and share it when new medications are being considered.

FAQs about pharmacogenomic testing

Is pharmacogenomic testing the same as genetic disease testing?

No. PGx testing is focused on medication response. It is usually not designed to diagnose inherited diseases, cancer risk syndromes, ancestry, carrier status, or traits. Some broad genetic tests may include PGx information, but the purpose and clinical confirmation standards can differ.

Can a PGx test tell me which pain medicine is safest?

Sometimes it can contribute useful information, especially for medications affected by CYP2D6 such as codeine and tramadol. But pain-medication safety also depends on age, breathing risk, kidney and liver function, opioid tolerance, other sedating medications, substance-use history, and the cause of pain.

Why did my report say a medication is risky when I have taken it for years?

A flagged gene-drug interaction does not automatically mean the medication is unsafe for you. If you are stable and tolerating it, your clinician may decide to continue it. The result may still be useful if the dose changes, a new interacting medication is added, or side effects appear.

Are direct-to-consumer pharmacogenetic reports enough for medical decisions?

Usually they should be treated as a starting point for discussion, not a stand-alone prescribing tool. The FDA-authorized 23andMe pharmacogenetic reports, for example, are intended to inform discussions with a healthcare provider; FDA clearance documents for later versions state that results should not be used to start, stop, or change treatment and may need confirmation by an independent clinical test before medical action. See the FDA’s 2018 announcement on the first direct-to-consumer pharmacogenetic test authorization.

Does a normal result mean I will not have side effects?

No. A normal metabolizer result only addresses the genes and variants tested. Side effects can occur for many reasons unrelated to those genes.

Should children have pharmacogenomic testing?

Sometimes, especially when a child is being considered for a medication with strong pediatric PGx evidence or has had unusual medication reactions. Pediatric decisions should involve the child’s clinician because dosing, development, diagnosis, and consent considerations differ from adults.

Can pharmacogenomic testing help with supplements?

Most clinically validated PGx guidance focuses on prescription medications. Some reports include supplements or lifestyle interpretations, but those claims may have weaker evidence and should be interpreted cautiously.

How long do results take?

Turnaround time varies. Some labs report within a few business days after receiving the sample; others may take one to several weeks depending on the test, lab workflow, insurance authorization, and whether confirmatory methods are needed.

Bottom line

Pharmacogenomic testing can be a valuable tool when it is ordered for the right reason, interpreted by someone who understands the medication decision, and combined with your full clinical picture. It is strongest for specific drug-gene pairs with clear evidence and weakest when sold as a broad promise to identify the perfect medication.

Before ordering, ask what decision the test will inform, what the total cost will be, how your data will be handled, and who will help translate the result into a safe plan. A good PGx report should reduce uncertainty—not create a color-coded shortcut that replaces careful prescribing.